8224 results for "canc*"

in 30.17 milliseconds.

• Expansion and cytotoxicity of mucosal T cells in enterocolitis associated with BCMA CAR-T cell therapy

  This study investigates immune effector cell enterocolitis (IEC-EC) associated with ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory multiple myeloma. IEC-EC was characterized by infiltration and expansion of clonal CAR-positive cytotoxic T-cell populations within the gastrointestinal tract. Molecular analyses were performed to characterize CAR T-cell clonality, persistence, vector integration, and genomic alterations associated with this complication. This dataset contains whole-genome sequencing (WGS) and whole-exome sequencing (WES) FASTQ files generated as part of the study and associated with the corresponding manuscript.

  Study EGAS50000002146

• Circulating tumour DNA in oligoprogressing metastatic castration-resistant prostate cancer treated with stereotactic body radiotherapy in the TRAP trial

  The TRAP trial (NCT03644303) reported that stereotactic body radiotherapy (SBRT) of up to two imaging-visible metastases in prostate cancer patients showing disease progression whilst continuing an androgen receptor pathway inhibitor (ARPI) improved outcomes. It is possible that the benefit from treatment is heterogeneous and patients with progressing sub-clinical metastases, not detected by imaging, derived no benefit from this intervention. The goal of this study was to determine if ctDNA levels detected before SBRT associates with worse outcome.

  Study EGAS50000002152

• Breast Cancer Atlas Research Consortium (BCARC)

  The Breast Cancer Atlas Research Consortium (BCARC) is an international translational research programme building a multi-modal atlas of breast cancer across subtypes, disease progression states, and treatment phases. Founding investigators span the Swarbrick Laboratory (Garvan Institute of Medical Research, Sydney), the Perou Laboratory (University of North Carolina at Chapel Hill), the Grimmond Laboratory (University of Melbourne Centre for Cancer Research), the Al'Khafaji Laboratory (Broad Institute of MIT and Harvard), and the Lundeberg Laboratory (KTH Royal Institute of Technology, Stockholm). Samples are drawn from primary and metastatic breast tumours together with matched adjacent tissues and where available, blood samples. All samples derive from participants consented under Garvan-approved research protocols. Access is controlled and governed by the BCARC data access agreement; requests are reviewed by the Data Access Committee named in the associated policy record

  Study EGAS00001008520

• Germline whole-genome sequencing (WGS) of colorectal cancer patients

  Whole-genome sequencing (WGS) data generated from matched germline blood DNA samples obtained from patients with primary or metastatic colorectal adenocarcinoma (n=37). These data were generated as part of a multiomic study integrating whole-genome sequencing with single-cell multiome profiling to investigate recurrent epigenetic alterations in colorectal cancer evolution and the tumour microenvironment.

  Dataset EGAD50000002942

• Whole Genome Sequencing (WGS) of Tumour Samples of Primary and Metastatic Colorectal Cancer

  WGS samples of primary (n=33) and metastatic (n=11) colorectal cancer tissues related to Livanova et al. manuscript 'Epigenetic evolution of colorectal cancer and its microenvironment reveals new vulnerabilities'

  Dataset EGAD50000002943

• Single-cell 10x Genomics Multiome ATAC-seq data from primary and metastatic colorectal cancers and normal colon tissues

  This dataset contains single-cell 10x Genomics Multiome ATAC-seq data from 33 primary colorectal cancer, 11 metastatic colorectal cancer, and 7 matched normal colon tissue samples generated as part of the study "Epigenetic evolution of colorectal cancer and its microenvironment reveals novel vulnerabilities."

  Dataset EGAD50000002944

• Single-cell 10x Genomics Multiome RNA-seq data from primary and metastatic colorectal cancers and normal colon tissues

  This dataset contains single-cell 10x Genomics Multiome RNA-seq data from 33 primary colorectal cancer, 11 metastatic colorectal cancer, and 7 matched normal colon tissue samples generated as part of the study "Epigenetic evolution of colorectal cancer and its microenvironment reveals novel vulnerabilities."

  Dataset EGAD50000002945

• Human breast cancer epigenetic sequencing data

  Controlled-access sequencing data generated from human breast tumor samples in the study "Epigenetic Heterogeneity in Breast Tumors with Implications for Disease Diagnosis and Monitoring". The dataset includes whole-genome DNA methylation sequencing, enzyme-mediated methylation sequencing of sorted tumor-cell populations, single-nucleus CUT&Tag, and single-cell RNA and chromatin-accessibility multiome sequencing. Raw sequencing data are provided as FASTQ files.

  Dataset EGAD50000002972

• ICGC PanCancer Analysis of Whole Genomes

  The Pancancer Analysis of Whole Genomes (PCAWG) study is an international collaboration to identify common patterns of mutation in more than 2,800 cancer whole genomes from the International Cancer Genome Consortium. Building upon previous work which examined cancer coding regions (Cancer Genome Atlas Research Network, The Cancer Genome Atlas Pan-Cancer analysis project, Nat. Genet. 2013 45:1113), this project is exploring the nature and consequences of somatic and germline variations in both coding and non-coding regions, with specific emphasis on cis-regulatory sites, non-coding RNAs, and large-scale structural alterations.

  Study EGAS00001001692

• CRCbiome: Gut metagenome of Norwegian screening participants using FIT sampling

  The study aims to characterize the gut metagenome of Norwegian screening participants and assess the ability of the gut metagenome to identify those at need for colonoscopy. Background: Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions. Methods: The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50–74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period. Discussion: The CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high.

  Study EGAS50000000170